455 related articles for article (PubMed ID: 38269272)
1. Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling.
Albadari N; Xie Y; Li W
Front Pharmacol; 2023; 14():1340401. PubMed ID: 38269272
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
Pohl M; Schmiegel W
Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
[TBL] [Abstract][Full Text] [Related]
3. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
4. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
Zhou J; Ji Q; Li Q
J Exp Clin Cancer Res; 2021 Oct; 40(1):328. PubMed ID: 34663410
[TBL] [Abstract][Full Text] [Related]
5. Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.
Lee MS; Kopetz S
Clin Colorectal Cancer; 2015 Dec; 14(4):203-18. PubMed ID: 26077270
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors.
Xu T; Wang X; Wang Z; Deng T; Qi C; Liu D; Li Y; Ji C; Li J; Shen L
Ther Adv Med Oncol; 2022; 14():17588359221105022. PubMed ID: 35747165
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
Pietrantonio F; Vernieri C; Siravegna G; Mennitto A; Berenato R; Perrone F; Gloghini A; Tamborini E; Lonardi S; Morano F; Picciani B; Busico A; Volpi CC; Martinetti A; Battaglin F; Bossi I; Pellegrinelli A; Milione M; Cremolini C; Di Bartolomeo M; Bardelli A; de Braud F
Clin Cancer Res; 2017 May; 23(10):2414-2422. PubMed ID: 27780856
[No Abstract] [Full Text] [Related]
8. Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment.
Gmeiner WH
Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473386
[TBL] [Abstract][Full Text] [Related]
9. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.
Linardou H; Dahabreh IJ; Kanaloupiti D; Siannis F; Bafaloukos D; Kosmidis P; Papadimitriou CA; Murray S
Lancet Oncol; 2008 Oct; 9(10):962-72. PubMed ID: 18804418
[TBL] [Abstract][Full Text] [Related]
10. Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies.
Wang N; Cao Y; Si C; Shao P; Su G; Wang K; Bao J; Yang L
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291943
[TBL] [Abstract][Full Text] [Related]
11. The potential therapeutic and prognostic impacts of the c-MET/HGF signaling pathway in colorectal cancer.
Parizadeh SM; Jafarzadeh-Esfehani R; Fazilat-Panah D; Hassanian SM; Shahidsales S; Khazaei M; Parizadeh SMR; Ghayour-Mobarhan M; Ferns GA; Avan A
IUBMB Life; 2019 Jul; 71(7):802-811. PubMed ID: 31116909
[TBL] [Abstract][Full Text] [Related]
12. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.
Sartore-Bianchi A; Amatu A; Porcu L; Ghezzi S; Lonardi S; Leone F; Bergamo F; Fenocchio E; Martinelli E; Borelli B; Tosi F; Racca P; Valtorta E; Bonoldi E; Martino C; Vaghi C; Marrapese G; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Torri V; Marsoni S; Siena S
Oncologist; 2019 Oct; 24(10):1395-1402. PubMed ID: 30952821
[TBL] [Abstract][Full Text] [Related]
13. Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
Lièvre A; Ouine B; Canet J; Cartier A; Amar Y; Cacheux W; Mariani O; Guimbaud R; Selves J; Lecomte T; Guyetant S; Bieche I; Berger F; de Koning L
Br J Cancer; 2017 Dec; 117(12):1819-1827. PubMed ID: 29024937
[TBL] [Abstract][Full Text] [Related]
14.
Ros J; Baraibar I; Sardo E; Mulet N; Salvà F; Argilés G; Martini G; Ciardiello D; Cuadra JL; Tabernero J; Élez E
Ther Adv Med Oncol; 2021; 13():1758835921992974. PubMed ID: 33747149
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers.
Kim SA; Park H; Kim KJ; Kim JW; Sung JH; Nam M; Lee JH; Jung EH; Suh KJ; Lee JY; Kim SH; Lee JO; Kim JW; Kim YJ; Kim JH; Bang SM; Lee JS; Lee KW
J Cancer Res Clin Oncol; 2022 Nov; 148(11):2995-3005. PubMed ID: 34853888
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer.
Kocoglu H; Velibeyoglu FM; Karaca M; Tural D
World J Gastrointest Oncol; 2016 Jan; 8(1):1-7. PubMed ID: 26798432
[TBL] [Abstract][Full Text] [Related]
17.
Li ZN; Zhao L; Yu LF; Wei MJ
Gastroenterol Rep (Oxf); 2020 Jun; 8(3):192-205. PubMed ID: 32665851
[TBL] [Abstract][Full Text] [Related]
18. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
19. LncRNA UCA1 mediates Cetuximab resistance in Colorectal Cancer via the MiR-495 and HGF/c-MET Pathways.
Yuan HH; Zhang XC; Wei XL; Zhang WJ; Du XX; Huang P; Chen H; Bai L; Zhang HF; Han Y
J Cancer; 2022; 13(1):253-267. PubMed ID: 34976187
[No Abstract] [Full Text] [Related]
20. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance.
Li QH; Wang YZ; Tu J; Liu CW; Yuan YJ; Lin R; He WL; Cai SR; He YL; Ye JN
Gastroenterol Rep (Oxf); 2020 Jun; 8(3):179-191. PubMed ID: 32665850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]